13

2024

-

08

Zhang Tongmei Team of Capital Medical University Latest Mol Cancer

Author:


Primary lung cancer is the most common malignant tumor in China. According to the data of the GLOBOCAN 2020, the incidence of lung cancer in China accounts for 37.0 percent of the global incidence of lung cancer and 39.8 percent of the related deaths.

On August 9, 2024,Zhang Tongmei Team of Capital Medical UniversityMolecular CancerPublished online entitled“A case of response to combination treatment with TSA-DC-CTL immunotherapy and osimertinib in EGFR mutated advanced lung adenocarcinoma” The research report.This report demonstrates that TSA-DC-CTL cell immunotherapy in combination with osimertinib for the treatment of advanced EGFR exon 19 deletionslung adenocarcinomaSafety and efficacy in patients. This provides a promising new treatment for patients with advanced lung cancer with EGFR mutations.

This study details a case of EGFR gene exon 19 deletion in a patient with advanced lung adenocarcinoma.A 46-year-old female patient was diagnosed with stage IVb left lung adenocarcinoma with multiple boneTransferandlymph node metastasis. After the tumor-specific antigenic peptide was identified, the patient received a combination of immunotherapy (TSA-DC-CTL) and oral osimertinib.Peripheral blood circulating immune cells and circulating tumor cells (CTCs) were monitored before and after treatment. UsePET-CTand CT scans to assess tumor response to treatment. observed a significant increase in the percentage of total lymphocytes in patients,CTCsThe number is significantly reduced. Imaging examination showed that the tumor metastasis was significantly reduced.

From the pathological and therapeutic point of view, lung cancer is dividednon-small cell lung cancer(NSCLC) and small cell lung cancer, of which NSCLC accounts for about 80-85%, including adenocarcinoma, squamous cell carcinoma and other histological subtypes. Standard treatment options for patients with non-small cell lung cancer include radiotherapy and chemotherapy. These methods often inhibit tumor cell proliferation or induce cell death in a non-specific manner, often leading to unsatisfactory results. The 5-year survival rate of patients is still very low, only 15-20%. Targeted therapy and active immunotherapy provide personalized treatment approaches. However, both treatments face challenges such as drug resistance, which hampers sustained treatment response and long-term survival. These issues highlight the need for better treatment strategies to bypass the limitations of existing treatments.

Cellular immunotherapy is a very effective cancer treatment, which is the fourth major cancer intervention after surgery, radiotherapy and chemotherapy.Dendritic cells (DCs)The main function is as an antigen presenting cell.DCsAntigen is captured and processed, presenting the antigen to the surface of CD8 + T cells via major histocompatibility complex (MHC) molecules, thereby activating the T cell immune response. Incomplete clearance of tumor cells by the immune system may contribute to the persistence of "immunoedited" tumors."Immune editing" is a key concept to describe the interaction between tumor and host immune system. This concept explains why the immune system, despite its ability to recognize and attack tumor cells, sometimes fails to eradicate them completely.

Tumor specific antigen peptide detection and TSA-DC-CTL vaccine combined with osimertinib treatment process

However, in many tumors,DCsfunction may be impaired, leading to reduced antigen presentation and immune escape. Thus, restoring or enhancingDCsfunction is a key strategy to improve the effectiveness of tumor immunotherapy.The use of TSA-loaded DC vaccines in cancer therapy has been extensively studied in clinical trials. OptimizedDCsIt is used to activate specific cytotoxic T lymphocytes (CTLs), effectively target and attack tumor cells, and shows great potential in the immune editing process. This approach has shown good clinical results in patients with advanced solid tumors. Therefore, it is necessary to further explore the oncogene targeted therapy combined with TSA-DC-CTL immunotherapy targeting tumor neoantigens as an effective treatment strategy for unresectable stage Ⅲ NSCLC.

In this study, the authors report a patient with advanced lung adenocarcinoma with EGFR exon 19 deletion who received TSA-induced in vitro expansion DC and CTL adoptive cellular immunotherapy combined with third-generation EGFR-TKI Osimertinib in February 2022.The combination therapy in this case not only shows the inhibitory effect of EGFR-TKI on tumor growth, but also highlights the unique role of TSA-DC-CTL immunotherapy in activating and strengthening the patient's immune system. This synergyIt may be a key factor in promoting a significant improvement in clinical outcomes for patients.Although the safety and short-term and long-term efficacy of TSA-DC-CTL as first-line therapy need to be further studied, this study provides a reference for the clinical treatment of patients with unresectable advanced lung cancer with EGFR gene mutations.

Chongqing Chongfan Technology Co., Ltd. Optical platform film thickness meter OCT optical coherence tomography LabVIEW control